Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

http://scihub22266oqcxt.onion/ 33832565!ä!33832565 Deprecated: Implicit conversion from float 221.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 221.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Dan+Med+J 2021 ; 68 (5): ä Nephropedia Template TP {{tp|p=33832565|t=2021. SARS-CoV-2 in saliva, oropharyngeal and nasopharyngeal specimens |pdf=|usr=}}{{33832565}} gab.com Text SARS-CoV-2 in saliva, oropharyngeal and nasopharyngeal specimens JO: Dan Med J http://www.kidney.de/pget.php?&tw=1&pmid=33832565 #FOAvip INTRODUCTION: The reference test to evaluate patients with suspected respiratory virus infection is a real-time reverse transcription-polymerase chain reaction (RT-PCR) from a nasopharyngeal swab (NPS). However, other specimen collection methods such as an oropharyngeal swab (OPS) or saliva specimen are also used for SARS-CoV-2 testing during the ongoing COVID-19 pandemic. However, it remains unclear if rates of SARS-CoV-2 detection differ between sampling methods. This study will compare the rates of SARS-CoV-2 detection by saliva, OPS, and NPS sampling in a public setting. METHODS: Individuals referred for outpatient SARS-CoV-2 testing will be invited to participate in a prospective clinical study. They will have saliva, OPS and NPS specimens collected that will be analysed separately for SARS-CoV-2 RNA by RT-PCR. The rate of SARS-CoV-2 detection in saliva, OPS and NPS will be compared using a logistic regression mixed-effect model analysis. A sample of 19,110 participants is required at an expected 1.5% test-positive rate in order to detect a 25.6% difference. The total sample size will be adjusted as the test-positive rate changes. CONCLUSIONS: This study will provide evidence for the optimal site of specimen collection to detect SARS-CoV-2. The results may help guide the health authorities. FUNDING: This is an investigator-initiated trial based on an unrestricted grant from the Novo Nordisk Foundation and the Aage og Johanne Louis-Hansens Fond. The foundations have had no say in the decisions on study design or reporting. TRIAL REGISTRATION: ClinicalTrials.gov (ID: NCT04715607). Twit Text FOAVip SARS-CoV-2 in saliva, oropharyngeal and nasopharyngeal specimens ????Dan Med J http://www.kidney.de/pget.php?&tw=1&pmid=33832565 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33832565 #FOAvip English Wikipedia <ref>{{Cite pmid|33832565}}</ref> SARS-CoV-2 in saliva, oropharyngeal and nasopharyngeal specimens #MMPMID33832565 Todsen T; Tolsgaard M; Folke F; Jakobsen KK; Ersboll AK; Benfield T; von Buchwald C; Kirkby N Dan Med J 2021[Apr]; 68 (5): ä PMID33832565show ga INTRODUCTION: The reference test to evaluate patients with suspected respiratory virus infection is a real-time reverse transcription-polymerase chain reaction (RT-PCR) from a nasopharyngeal swab (NPS). However, other specimen collection methods such as an oropharyngeal swab (OPS) or saliva specimen are also used for SARS-CoV-2 testing during the ongoing COVID-19 pandemic. However, it remains unclear if rates of SARS-CoV-2 detection differ between sampling methods. This study will compare the rates of SARS-CoV-2 detection by saliva, OPS, and NPS sampling in a public setting. METHODS: Individuals referred for outpatient SARS-CoV-2 testing will be invited to participate in a prospective clinical study. They will have saliva, OPS and NPS specimens collected that will be analysed separately for SARS-CoV-2 RNA by RT-PCR. The rate of SARS-CoV-2 detection in saliva, OPS and NPS will be compared using a logistic regression mixed-effect model analysis. A sample of 19,110 participants is required at an expected 1.5% test-positive rate in order to detect a 25.6% difference. The total sample size will be adjusted as the test-positive rate changes. CONCLUSIONS: This study will provide evidence for the optimal site of specimen collection to detect SARS-CoV-2. The results may help guide the health authorities. FUNDING: This is an investigator-initiated trial based on an unrestricted grant from the Novo Nordisk Foundation and the Aage og Johanne Louis-Hansens Fond. The foundations have had no say in the decisions on study design or reporting. TRIAL REGISTRATION: ClinicalTrials.gov (ID: NCT04715607). |COVID-19 Nucleic Acid Testing[MESH] |COVID-19/*diagnosis[MESH] |Humans[MESH] |Logistic Models[MESH] |Nasopharynx/*virology[MESH] |Oropharynx/*virology[MESH] |Reverse Transcriptase Polymerase Chain Reaction[MESH] |SARS-CoV-2/*isolation & purification[MESH] |Saliva/*virology[MESH]SARS-CoV-2 in saliva, oropharyngeal and nasopharyngeal specimens (epmc).pdf DeepDyve Pubget Overpricing